Jinse Medical, a Leading Mixed Reality Surgical Navigation Company, Secures Tens of Millions of RMB in Series A and A+ Financing

VCBeat (WeChat:(VCBeat) It has been learned that Changzhou MiDIVI Medical Information Technology Co., Ltd. (hereinafter referred to as “MiDIVI”) announced the successive completion of tens of millions of RMB in its Series A and Series A+ financing rounds. The two rounds were conducted in close succession. The Series A round was led by Weilin Capital, with participation from Changzhou Venture Capital and Probe Capital. The Series A+ round was exclusively invested by the renowned industrial capital Shangyuan Capital, with Probe Capital serving as the exclusive financial advisor. The proceeds from these financing rounds will be used to accelerate the R&D and commercialization of MiDIVI’s orthopedic and oncology product pipelines, as well as to expand the company’s team.

Regarding the consecutive recognition from investors, Pan Zhen, founder of MiDIVI, stated that this success stems from the expanding application of mixed reality (MR) technology in the medical field, combined with the company’s sustained investment in its MR surgical platform and accumulation of clinical experience over the past few years. This has fostered unique insights and enabled the validation of a viable business model for MR medical products, delivering significant improvements in therapeutic outcomes, patient experience, and workflow optimization—placing MiDIVI at the forefront globally. Following this round of financing, MiDIVI will expand its product applications from orthopedics and oncology to additional clinical specialties and surgical procedures.

MiDIVI, founded in 2017, is a medical pioneer as the first company to offer a mixed reality surgical platform that simultaneously navigates both soft and hard tissues. As early as 2019, it obtained China’s first product registration certificate based on mixed reality technology. Its independently developed MR (Mixed Reality) series of products covers various application scenarios, including surgical medical education, clinical practice, remote collaboration, and surgical navigation, bringing new innovation-driven factors to the technological iteration of smart surgery in the new era.

MiDIVI has accumulated profound expertise in the field of mixed reality (MR) healthcare. The company has secured over ten patents, with dozens more invention patent applications pending. Its independently developed MR-based knee surgery navigation system passed type testing in 2021 and has entered the registration-related clinical trial phase. It is expected to receive regulatory approval for market launch soon, positioning MiDIVI as the first domestic company in the MR surgical navigation sector. Meanwhile, its MR-based lung navigation system, currently under development, has completed animal trials and entered investigator-initiated clinical studies. It is projected to enter the regulatory registration phase within the year, making it the first known MR-based surgical navigation product under development globally, based on publicly available information. Currently, MiDIVI’s pipeline covers most surgical scenarios, and the company aims to provide smart surgical solutions worldwide in the future.

With the successful completion of its Series A+ financing, MiDIVI will accelerate its industrialization strategy. With the support of industrial capital, it has entered into more comprehensive and in-depth cooperation with Weigao Group in the medical sector. At the clinical level, MiDIVI has established integrated production-research partnerships with dozens of hospitals, including The First Affiliated Hospital of Zhejiang University School of Medicine, Xiangya Hospital of Central South University, Nanjing Hospital Affiliated to Nanjing Medical University, Shanghai Chest Hospital, Shanghai Ninth People’s Hospital, The First Affiliated Hospital of Zhengzhou University, Wuhan Union Hospital, and Shanghai Changhai Hospital. Furthermore, many renowned multinational corporations, such as Microsoft, Siemens Healthineers, and AstraZeneca, are actively engaging in technical collaborations with MiDIVI on smart surgical products. In the future, MiDIVI is expected to introduce a broader range of smart surgical solutions into the global industry chain.

Yan Chen, Partner at Shangyuan Capitalstated, “We are greatly honored to participate in this round of financing. As a global leader in applying mixed reality technology to the healthcare sector, MiDIVI has our strong confidence in its technological reserves in cutting-edge fields such as mixed reality, artificial intelligence, and cloud computing. We also hope that MiDIVI’s products will better serve healthcare, contributing to the ‘intelligent, minimally invasive, and digital’ development of the medical industry.””

Zhang Weiqiao, General Manager of Weilin Ventures“MiDIVI is a pioneer in applying mixed reality technology to clinical medical practice in China. With substantial expertise in virtual reality, artificial intelligence, and big data algorithms, the company has already initiated clinical trials with multiple leading Grade A tertiary hospitals. We have every reason to believe that MiDIVI will bring innovative vitality to assisted medical diagnosis and surgery.””

Guo Ping, Investment Director at Qitai Capital and General Manager of Changzhou Science and Education City Industrial Investment Fundstated: “Since settling in Changzhou Science and Education Town, MiDIVI has continuously invested in R&D, integrating mixed reality with healthcare, with its overall technology leading domestically. In December 2019, it successfully obtained China’s first registration certificate for a mixed reality medical product, successfully introducing mixed reality and holographic imaging into the medical field. It is a company with unicorn potential.””

Du Meng, Vice President of Investment at Kefa Capitalstated: “MiDIVI’s technical team primarily hails from renowned companies such as Siemens Healthineers and Microsoft, bringing extensive R&D experience. We recognize Mr. Pan Zhen’s capabilities in management, operations, and market expansion, as well as the R&D leadership provided by CTO Mr. Chen Liang. Accordingly, we invested in MiDIVI during its angel round. The company has accurately positioned itself in the markets for orthopedic joint replacement and holographic-guided sublobar lung resection, which hold broad prospects. We look forward to the company’s sustained long-term development.””

Yang Danning, Partner at Probes Capital, as the exclusive financial advisor for this financing roundstated: “By deeply integrating mixed reality technology with clinical surgical procedures, MiDIVI has established an industry-leading real-time surgical navigation system. What excites us even more is that the company’s innovative solutions are poised to cover dozens of surgical procedures involving both soft and hard tissues in the future, and, thanks to their remarkable ease of use and cost-effectiveness, become the ‘new infrastructure’ for surgical operations in China. We thank the MiDIVI team for their trust and are honored to accompany the company on its continued journey forward.””

Shangyuan Capital is a venture capital fund jointly established by investors including Shandong Provincial State-owned Assets Investment Holding Group, Shandong New Kinetic Energy Conversion Fund, and Weigao Group. Focusing on investing in innovative enterprises in the medical device sector, the team is committed to integrating resources from government, industry, and finance to support entrepreneurial innovation and industrial upgrading.

Weilin Venture Capital is an investment institution with extensive experience in capital operations, dedicated to providing comprehensive capital planning for enterprises at all stages of development. Weilin Venture Capital focuses on high-growth investment opportunities in new products, new technologies, and new markets, offering long-term support to foster corporate growth. It is also committed to in-depth industry research to identify high-quality companies with strong core technological and industry barriers. The firm has established a diversified portfolio across sectors including new energy, energy conservation and environmental protection, film and television culture, electronic information, cybersecurity, high-end equipment, and healthcare.

Changzhou Venture Capital—Qitai Capital has been dedicated to identifying early-stage technology innovation projects since taking over the management of the Science and Education City Fund. Focusing on three major industries—artificial intelligence, robotics, and next-generation information technology—it has cumulatively invested RMB 50 million in early- to mid-stage sci-tech enterprises over the past year. Looking ahead, Qitai Capital will continue to strengthen its efforts with the Science and Education City Fund, facilitating effective connections between high-quality enterprises in the Science and Education City and capital, markets, and government resources. This initiative aims to propel Changzhou Science and Education City to strive for a leading position as the “vanguard of the Southern Jiangsu National Independent Innovation Demonstration Zone” and serve as a “new engine for Changzhou’s high-quality development.”

Probe Capital is an asset incubation and investment & financing platform focused on the healthcare and life sciences industries. Its founders hail from renowned domestic medical venture capital firms, and the company has facilitated billions of RMB in financing transactions, establishing itself as a leading financial advisory (FA) institution in China’s healthcare sector.